Skip to content

Medtronic's Dividend Loyalty Shines Amid Stock Market Struggles and Spinoff Plans

One retiree banks on Medtronic's half-century of dividends to fund their future—and pass wealth to the next generation. But can the company outpace rivals after its diabetes spinoff?

The image shows a paper with text and a logo on it, along with numbers at the bottom. The text...
The image shows a paper with text and a logo on it, along with numbers at the bottom. The text reads "Shand & Henning Patentes, Improved Artificial Leg".

Medtronic's Dividend Loyalty Shines Amid Stock Market Struggles and Spinoff Plans

Medtronic remains a key player in the medical device industry, despite recent finance challenges. The company has maintained a strong dividend record, paying shareholders for nearly half a century. One long-term investor now relies on these dividends for retirement income and plans to leave the shares to their daughter as an inheritance.

Medtronic has grown into one of the world's largest medical technology firms. Its operations span cardiovascular, neuroscience, and medical-surgical fields, though its diabetes division is set to split off. The company announced this separation in October 2023, but since then, its stock market value has fallen by roughly 15% to $105 billion as of February 2026. Competitors like Boston Scientific and Stryker have outperformed it, rising by 25% and 18% respectively, due to concerns over slower growth in Medtronic's remaining businesses.

Despite these setbacks, Medtronic continues to attract income-focused investors. The firm has raised its dividend every year for 48 years, nearing the elite status of a Dividend King. Its current yield stands at nearly 3%, a historically high level. One shareholder uses these payouts to cover living expenses in retirement while reinvesting a portion to grow wealth over time.

Looking ahead, Medtronic forecasts stock market revenue growth of 5.5% in fiscal 2026. The company's long-standing reputation for innovation still underpins its position in the market. Yet, investor confidence remains shaky as the business navigates the spinoff and seeks to stabilise performance.

Medtronic's dividend reliability and market presence keep it on the radar of long-term investors. The author's strategy—using payouts for bills while compounding reinvested funds—highlights its appeal. Meanwhile, the planned inheritance transfer reflects confidence in the company's enduring value, despite recent struggles.

Read also:

Latest